Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Gains from Investment Securities: 2010-2023

Historic Gains from Investment Securities for China Pharma Holdings (CPHI) over the last 8 years, with Dec 2023 value amounting to $156,273.

  • China Pharma Holdings' Gains from Investment Securities was N/A to $201,865 in Q4 2023 from the same period last year, while for Dec 2023 it was -$2,124, marking a year-over-year change of. This contributed to the annual value of $156,273 for FY2023, which is N/A change from last year.
  • According to the latest figures from FY2023, China Pharma Holdings' Gains from Investment Securities is $156,273, which was down 7.31% from $168,606 recorded in FY2021.
  • China Pharma Holdings' 5-year Gains from Investment Securities high stood at $229,673 for FY2020, and its period low was $156,273 during FY2023.
  • Its 2-year average for Gains from Investment Securities is $162,440, with a median of $162,440 in 2021.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first increased by 0.01% in 2020, then dropped by 26.59% in 2021.
  • Over the past 4 years, China Pharma Holdings' Gains from Investment Securities (Yearly) stood at $229,644 in 2019, then rose by 0.01% to $229,673 in 2020, then fell by 26.59% to $168,606 in 2021, then reached $156,273 in 2023.